Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H20N6O.2ClH |
Molecular Weight | 421.324 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.O=C(NC1=CC=CC(=C1)C2=NCCN2)NC3=CC=CC(=C3)C4=NCCN4
InChI
InChIKey=MLRXMTYSQKIKAK-UHFFFAOYSA-N
InChI=1S/C19H20N6O.2ClH/c26-19(24-15-5-1-3-13(11-15)17-20-7-8-21-17)25-16-6-2-4-14(12-16)18-22-9-10-23-18;;/h1-6,11-12H,7-10H2,(H,20,21)(H,22,23)(H2,24,25,26);2*1H
Imidocarb is a carbanilide derivative with antiprotozoal activity. It is usually administered as the dipropionate salt. Imidocarb is a drug sold under the brand name Imizol and is used to treat canine ehrlichiosis. wo mechanisms of action have been proposed:
As the effect of imidocarb on Trypanosoma brucei is antagonized by excess polyamines, it is has been suggested that imidocarb interferes with their production and/or use. Imidocarb blocks the entry of inositol into erythrocytes containing Babesia, resulting in starvation of the parasite. It is generally accepted in that imidocarb has anticholinesterase activity.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4768 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27301742 |
|||
Target ID: CHEMBL2966 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27301742 |
|||
Target ID: CHEMBL220 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20053484 |
590.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Imizol Approved UseFor the treatment of babesiosis in dogs with clinical signs and/or demonstrated Babesia organisms in the blood. Launch Date1997 |
|||
Curative | IMIDOCARB Approved UseFor treatment of babesiosis in cattle and horses Launch Date2001 |
PubMed
Title | Date | PubMed |
---|---|---|
Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia. | 1988 Jun |
|
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992 Sep |
|
Determination of whole blood cholinesterase in different animal species using specific substrates. | 2001 Jun |
|
Depletion and bioavailability of imidocarb residues in sheep and goat tissues. | 2002 Apr |
|
Electron microscopic investigations on stages of dog piroplasms cultured in vitro: Asian isolates of Babesia gibsoni and strains of B. canis from France and Hungary. | 2002 Jan |
|
Evaluation of certain veterinary drug residues in food. | 2003 |
|
First isolation and molecular characterization of Ehrlichia canis in Spain. | 2004 Nov 10 |
|
Identification of anti-babesial activity for four ethnoveterinary plants in vitro. | 2005 Jun 10 |
|
Pharmacokinetics and mammary elimination of imidocarb in sheep and goats. | 2006 Jul |
|
Flow cytometric evaluation of selected antimicrobial efficacy for clearance of Anaplasma marginale in short-term erythrocyte cultures. | 2006 Jun |
|
Effect of imidocarb and levamisole on the experimental infection of BALB/c mice by Leishmania (Leishmania) amazonensis. | 2006 Jun 30 |
|
Clinicopathological changes and effect of imidocarb therapy in dogs experimentally infected with Babesia canis. | 2006 Mar |
|
Chemotherapy against babesiosis. | 2006 May 31 |
|
Histological and ultrastructural studies of renal lesions in Babesia canis infected dogs treated with imidocarb. | 2007 Dec |
|
Canine vector-borne diseases in Brazil. | 2008 Aug 8 |
|
Treatment of Mycoplasma wenyonii infection in cows with imidocarb dipropionate injection-acupuncture. | 2008 Dec |
|
Repeated high dose imidocarb dipropionate treatment did not eliminate Babesia caballi from naturally infected horses as determined by PCR-reverse line blot hybridization. | 2008 Feb 14 |
|
Detection of persistent Cytauxzoon felis infection by polymerase chain reaction in three asymptomatic domestic cats. | 2008 Jul |
|
An unusual form of canine babesiosis. | 2008 Mar |
|
Putative clinical piroplasmosis in a Burchell's zebra (Equus quagga burchelli). | 2009 Dec |
|
Detection of a large unnamed Babesia piroplasm originally identified in dogs in North Carolina in a dog with no history of travel to that state. | 2009 Oct 1 |
|
Failure of imidocarb dipropionate to eliminate Hepatozoon canis in naturally infected dogs based on parasitological and molecular evaluation methods. | 2010 Aug 4 |
|
First case of babesiosis caused by Babesia canis canis in a dog from Norway. | 2010 Aug 4 |
|
Haemotropic mycoplasmas: what's their real significance in cats? | 2010 May |
|
Detection of Babesia divergens in southern Norway by using an immunofluorescence antibody test in cow sera. | 2010 Oct 6 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/vet/imizol.html
Use intramuscularly or subcutaneously at a rate of 6.6 mg/kg (3 mg/lb) body weight. Repeat the dose in two (2) weeks, for a total of two (2) treatments.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2242963
The concentration of Imidocarb causing 50% inhibition of [3H]hypoxanthine incorporation (ID50 value) by Babesia bovis (Lismore and Samford isolates) cultured in vitro for Imidocarb was determined to be 3 ng/ml (8.6 nM).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C277
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID30201240
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
300000023746
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
m6226
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
C76422
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
CHEMBL427342
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
226-179-7
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
51189
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
21388
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
KCC1V76AH8
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
5318-76-3
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD